drugset / Trial / NCT03010202
The PROLONG Trial - Rituximab Maintenance Therapy in ITP
Phase 3
Unknown
136 enrolled
Ostfold Hospital Trust
Cairo University · collabCentre Hôpital Universitaire Farhat Hached · collabHaukeland University Hospital · collabHelse Stavanger HF · collabHenri Mondor University Hospital · collabOdense University Hospital · collabOslo University Hospital · collabSt. Olavs Hospital · collabUniversity Hospital of North Norway · collabUniversity Hospital, Akershus · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a two phase study that aims to evaluate if low-dose Rituximab maintenance therapy may prolong the the effect of Rituximab in immune thrombocytopenia.
Timeline
- Start
- 2016-12
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 500 mg | Intravenous |